http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1359265-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_366a19489c5e7eec53d9d57c5ca5657b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C237-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166 |
| filingDate | 1972-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1974-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1359265-A |
| titleOfInvention | Substituted cyclic urea derivatives and pharmaceutical compositions containing them |
| abstract | 1359265 Substituted cyclic ureas and their use in pharmaceutical compositions ASTA-WERKE AG 6 Oct 1972 [9 Oct 1971] 46141/72 Heading C2C The invention comprises compounds of Formula I: wherein m is 2 or 3, R is a straight or branched (C 2-4 ) alkylene group, R 1 is saturated or unsaturated, straight or branched (C 1-8 ) hydrocarbon group, R 2 and R 3 which may be the same or different, are a hydrogen atom or (C 1-4 ) alkyl group, or R 2 and R 3 together with the nitrogen atom to which they are attached, are a pyrrolidone, piperidine, homopiperidine or morpholine group and A is the residue of a piperazine, 1,4- diazacycloheptane, 1,4-diazacyclo-octane, or 1,5-diazacyclo-octane, these cyclic residues being bound to the neighbouring groups by their two nitrogen atoms or A is the residue of an aliphatic amine of formula B being a polymethylene chain having from 2 to 3 carbon atoms, and R 4 and R 5 each represent a hydrogen atom or an (C 1-4 ) alkyl group; and the salts of these compounds formed with pharmacologically acceptable acids. These compounds may be obtained by reacting equivalent amounts of the compounds of the following general formulµ in a stepwise fashion with one another in the presence of an alkaline condensation agent at an elevated temperature, in the above formulµ X represents a radical of a reactive ester, Y<SP>1</SP> is a halogen atom or an alkyl or phenoxy group, and m, R, R 1 , and R 2 and A are as defined above. Many compounds are specified in the examples. The examples also describe the preparation of the following intermediates: Example I:- N - diethylcarbamoyl - 4 - piperazine by the hydrolysis of N - carbethoxy - N<SP>1</SP> - (diethylcarbamoyl)-piperazine which is prepared by the reaction of mono-carbethoxypiperazine and N,N-diethylcarbamoyl chloride; Example 13:- Diethylcarbamoyl - 4 - # - hydroxyethyl piperazine by the reaction of diethylcarbamoyl piperazine and ethylene oxide (see also a similar intermediate in Example 18); Example 18:-1-Diethylcarbamoyl - 4 - (# - chloropropyl) - piperazine by the treatment of 1-diethylcarbamoyl-4-(#- hydroxypropyl)-piperazine with thionyl chloride; Example 23:-2-[2-(1-Methyl-2-oxo-imidazolidin-3-yl)-ethylamino]-ethyl urea, by the reaction of N-[2-(1-methyl-2-oxo-imidazolidin-3- yl)-ethyl]ethylene diamine with carbamic acid phenyl ester; Example 24:-1-(2-Hydrazinoethyl - 3 - methyl - 2 - imidazolidinone by the reaction of hydrazine hydrate with 1-methyl-3- # - chloroethyl - imidazolidone - (2); Example 25 (a):-p-Toluene sulphonic acid ester of 1-(#- hydroxyethyl) - 3 - methyl - 2 - imidazolidinone by the reaction of toluene sulphonyl chloride with 1 - (# - hydroxyethyl) - 3 - methyl - 2 - imidazolidinone. The invention also comprises a pharmaceutical composition having antimycotic and antiviral effectiveness which contains as an active compound a cyclic urea derivative according to the invention. |
| priorityDate | 1971-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 73.